Vimarsana
Biggest News Aggregation in the World

Double Blinded News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Double Blinded. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Double Blinded Today - Breaking & Trending Today

MyJournals.org - Science - 'Pharmaceuticals, Vol. 16, Pages 799: Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients' (Pharmaceuticals) - Vimarsana News

MyJournals.org - Science - 'Pharmaceuticals, Vol. 16, Pages 799: Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients' (Pharmaceuticals)

MyJournals.org - Science - 'Pharmaceuticals, Vol. 16, Pages 799: Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients' (Pharmaceuticals)

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027 - Vimarsana News

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

Financialnewsmedia.com: Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027 - Vimarsana News

Financialnewsmedia.com: Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

FinancialNewsMedia.com News Commentary PALM BEACH, Fla, Nov. 15, 2022 /PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs.

Organicell Regenerative Medicine, Inc.: Organicell Activates COPD Trial at Mayo Clinic - Vimarsana News

Organicell Regenerative Medicine, Inc.: Organicell Activates COPD Trial at Mayo Clinic

Clinical Trial UpdateDAVIE, FL / ACCESSWIRE / November 15, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Vimarsana News

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

-- CK0803 are neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells -- CK0803 represents the company's fifth program to receive IND Clearance utilizing Cellenkos' proprietary CRANEtechnology HOUSTON, Sept. 22, 2022 /PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory disorders and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 safety stu...